Eisai Clinical Trials
Study Overview
E7080
lenvatinib
NCT03418922, JapicCTI-183850, jRCT2080223794
Jan 2018 - Dec 2022
Hepatocellular Carcinoma (HCC)
1. Part 1: Number of Participants with Dose-Limiting Toxicities (DLTs)
2. Part 1 and Part 2: Number of Participants with Any Serious and/or Non-serious Adverse Event
2. Part 1 and Part 2: Number of Participants with Any Serious and/or Non-serious Adverse Event
-
Males and females 20 Years and older (Adult, Older Adult)
-
Completed -
Phase 1
JapanData Sharing
ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.
CSDR Sharing is not available for this study.
CSDR Availability Clinical Trial Data Redacted documents may be available upon request for this study.
Document type Availability Protocol SAP Sample CRF Full CSR